Clinical Trial Update: CLEAR Study: Clinical Experience Acquired With Raptiva Study [Phase 3]

View source ↗

Summary

An update on the Phase 3 CLEAR study reports clinical experience with efalizumab (Raptiva) in patients with moderate-to-severe psoriasis. The study status is co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Raptiva (efalizumab)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Moderate to Severe Psoriasis | Phase 3 | Status: COMPLETED